Introduction:
Gastrointestinal disorders affect a significant population of people worldwide, leading to chronic pain and discomfort. In China, this problem is particularly pervasive, with millions of citizens suffering from irritable bowel syndrome (IBS) and chronic constipation. However, the good news is that Linaclotide-API, a revolutionary medication, can help alleviate these issues and bring relief to those suffering from gastrointestinal disorders.
What is Linaclotide-API?
Linaclotide-API is an innovative drug that targets specific receptors in the intestine to stimulate secretion and improve motility, resulting in reduced symptoms of IBS and chronic constipation. This medication has been approved by regulatory bodies in several countries, including China, where it is available in various forms, including capsules and injections.
Benefits of Linaclotide-API:
Linaclotide-API offers a range of benefits for individuals suffering from gastrointestinal disorders. Firstly, it provides relief from chronic constipation and IBS, which are debilitating conditions that can significantly impact quality of life. Secondly, it has fewer side effects than traditional medications used to treat these disorders, making it a safer option for many patients. Additionally, Linaclotide-API has been shown to be effective in clinical trials, providing scientific evidence of its efficacy.
Linaclotide-API is a revolutionary drug used to treat gastrointestinal disorders such as chronic constipation and irritable bowel syndrome with constipation (IBS-C). The active ingredient of this drug, linaclotide, works by binding to specific receptors in the intestine, leading to an increase in fluid secretion and motility. Since its approval by the US Food and Drug Administration (FDA) in 2012, linaclotide has become an essential medication for millions of patients worldwide.
The Chinese Market:
China is the world’s most populous country, with over 1.4 billion people, and a rapidly growing economy. The demand for drugs in China is high due to the aging population, increasing incidence of chronic diseases, and rising incomes. The gastrointestinal disorder market is expected to reach $6.8 billion by 2025, with chronic constipation and IBS-C being the most prevalent among them.
Linaclotide-API in China:
Linaclotide-API has gained significant attention in China due to its effectiveness in treating gastrointestinal disorders. In 2020, Luye Pharma Group, one of China’s leading pharmaceutical companies, obtained the exclusive license to develop and market linaclotide-API in China. The company plans to conduct clinical trials and launch the product in the near
China Chendu Shengnuo Biotechnology Co., Ltd which is mainly engaged in the research of polypeptide, polypeptide drug.
Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .
We have strong technical force, can carry out peptide product research and development, and meet the production and manufacturing capacity of international standards, and obtain the FDA certification.
Our products have been exported to Europe, America, Japan, Australia, Southeast Asia, the Middle East, South America, Africa and other countries and regions.
Other Polypeptide APIs Products
peptide synthesis companies
| Polypeptide APIs Products |
| US-DMF LIST |
| Beauty peptides |
| Chinese cGMP APIs |
| Mexico Registered APIs |
| Research Peptide APIs for Regulatory Market |
| Polypeptide Preparation |
| Kaijie bio medicine Peptide APIs |